Inhibikase Therapeutics reported earnings of -$ 0.10 per IKT share on Nov 10, 2026, falling short of analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.11 |
| Earnings Per Share (Surprise) | -$ 0.10 (+$ 0.01114) |
| Last Year's EPS | -$ 0.12 |
| EPS YoY Change |
Out of the last 37 earnings reporting periods, Inhibikase Therapeutics beat analysts’ expectations 7 times and fell short of expectations 14 time(s). Inhibikase Therapeutics reported earnings per share of -$ 0.10 in the last report surpassing an estimated EPS of -$ 0.11 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.11 | -$ 0.10 | -$ 0.13 | |
| Aug 11, 2026 | -$ 0.11 | -$ 0.11 | -$ 0.11 | |
| May 12, 2026 | -$ 0.10 | -$ 0.10 | -$ 0.15 | |
| Mar 26, 2026 | -$ 0.12 | -$ 0.09 | $ 0.88 | |
| Nov 14, 2025 | -$ 0.13 | -$ 0.13 | -$ 0.63 | |
| Aug 14, 2025 | -$ 0.09 | -$ 0.11 | -$ 0.65 | |
| May 14, 2025 | -$ 0.11 | -$ 0.15 | -$ 0.66 | |
| Mar 27, 2025 | -$ 0.10 | $ 0.88 | -$ 0.73 | |
| Mar 26, 2025 | -$ 0.10 | -$ 0.63 | -$ 0.63 | |
| Nov 14, 2024 | -$ 0.38 | -$ 0.65 | -$ 0.86 | |
| Aug 14, 2024 | -$ 0.58 | -$ 0.66 | -$ 1.11 | |
| May 15, 2024 | -$ 0.79 | -$ 0.73 | -$ 0.96 | |
| Mar 27, 2024 | -$ 0.78 | -$ 0.63 | -$ 1.02 | |
| Nov 14, 2023 | -$ 1.12 | -$ 0.86 | -$ 0.20 | |
| Aug 14, 2023 | -$ 0.92 | -$ 1.11 | -$ 1.08 | |
| May 16, 2023 | -$ 0.15 | -$ 0.96 | -$ 1.08 | |
| Mar 31, 2023 | -$ 1.14 | -$ 1.02 | -$ 1.08 | |
| Mar 30, 2023 | - | -$ 0.20 | -$ 1.20 | |
| Nov 14, 2022 | -$ 0.18 | -$ 1.08 | -$ 1.08 | |
| Aug 12, 2022 | -$ 0.19 | -$ 1.08 | -$ 1.32 |
Inhibikase Therapeutics’s stock was trading at $ 1.68 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, IKT’s price decreased to $ 1.63 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.10 | $ 1.68 | $ 1.63 | |
| Aug 11, 2026 | -$ 0.11 | $ 2.46 | $ 2.40 | |
| May 12, 2026 | -$ 0.10 | $ 2.03 | $ 1.90 | |
| Mar 26, 2026 | -$ 0.09 | $ 1.63 | $ 1.68 | |
| Nov 14, 2025 | -$ 0.13 | $ 1.60 | $ 1.52 | |
| Aug 14, 2025 | -$ 0.11 | $ 1.71 | $ 1.75 | |
| May 14, 2025 | -$ 0.15 | $ 2.23 | $ 2.03 | |
| Mar 27, 2025 | $ 0.88 | $ 2.39 | $ 2.29 | |
| Mar 26, 2025 | -$ 0.63 | $ 2.37 | $ 2.37 | |
| Nov 14, 2024 | -$ 0.65 | $ 2.42 | $ 2.05 | |
| Aug 14, 2024 | -$ 0.66 | $ 1.38 | $ 1.23 | |
| May 15, 2024 | -$ 0.73 | $ 1.54 | $ 1.76 | |
| Mar 27, 2024 | -$ 0.63 | $ 2.29 | $ 2.16 | |
| Nov 14, 2023 | -$ 0.86 | $ 0.9374 | $ 0.94 | |
| Aug 14, 2023 | -$ 1.11 | $ 2.46 | $ 2.34 | |
| May 16, 2023 | -$ 0.96 | $ 3.96 | $ 3.96 | |
| Mar 31, 2023 | -$ 1.02 | $ 4.08 | $ 3.71 | |
| Mar 30, 2023 | -$ 0.20 | $ 4.20 | $ 3.95 | |
| Nov 14, 2022 | -$ 1.08 | $ 3.00 | $ 3.72 | |
| Aug 12, 2022 | -$ 1.08 | $ 5.33 | $ 4.79 |
Inhibikase Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Inhibikase Therapeutics beat analysts’ expectations during the last earnings period by
